Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig

Journal of Pharmacological and Toxicological Methods

Volumn 66, Issue 2, 2012, Pages 125-134

  Guns, P J ^a   Johnson, D M ^a   Weltens, E ^a   Lissens, J ^a  

^a Bio Plus Safety Pharmacology   (Belgium)

Author keywords

Anesthetized guinea pig; Electro mechanical window; ICH S7B; Methods; QT interval; Torsades de Pointes

Indexed keywords

ADRENALIN; AMIODARONE; CIPROFLOXACIN; DOFETILIDE; DOMPERIDONE; HALOPERIDOL; MOXIFLOXACIN; PENTOBARBITAL; QUINIDINE; RANOLAZINE; TERFENADINE; VERAPAMIL;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ARTICLE; CLINICAL PROTOCOL; DRUG MECHANISM; ELECTRIC ACTIVITY; ELECTROCARDIOGRAM; FEMALE; GUINEA PIG; HEART LEFT VENTRICLE PRESSURE; MICROELECTROMECHANICAL SYSTEM; NONHUMAN; PREDICTION; QT INTERVAL; QT PROLONGATION; TORSADE DES POINTES;

ANESTHESIA; ANIMALS; DISEASE MODELS, ANIMAL; DRUG ANTAGONISM; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; EPINEPHRINE; FEMALE; GUINEA PIGS; HEART RATE; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; SYMPATHETIC NERVOUS SYSTEM; TORSADES DE POINTES; TOXICITY TESTS;

ANIMALIA; CAVIA;

EID: 84865615352     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2012.03.007     Document Type: Article

References (45)

1. Altin T., Ozcan O., Turhan S., Ongun O.A., Akyurek O., Karaoguz R., et al. Torsade de pointes associated with moxifloxacin: A rare but potentially fatal adverse event. Canadian Journal of Cardiology 2007, 23:907-908.
2. Antoons G., Oros A., Beekman J.D., Engelen M.A., Houtman M.J., Belardinelli L., et al. Late Na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. Journal of the American College of Cardiology 2010, 55:801-809.
3. Antzelevitch C. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm 2005, 2:S9-S15.
4. Antzelevitch C., Burashnikov A., Sicouri S., Belardinelli L. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm 2011, 8:1281-1290.
5. Bass A., Valentin J.P., Fossa A.A., Volders P.G. Points to consider emerging from a mini-workshop on cardiac safety: Assessing torsades de pointes liability. Journal of Pharmacological and Toxicological Methods 2007, 56:91-94.
6. Carlsson L. The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes. Pharmacological & Therapeutics 2008, 119:160-167.
7. Carlsson L., Abrahamsson C., Andersson B., Duker G., Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: Importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovascular Research 1993, 27:2186-2193.
8. Carlsson L., Almgren O., Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: Etiology and interventions. Journal of Cardiovascular Pharmacology 1990, 16:276-285.
9. Carlsson L., Drews L., Duker G., Schiller-Linhardt G. Attenuation of proarrhythmias related to delayed repolarization by low-dose lidocaine in the anesthetized rabbit. Journal of Pharmacology and Experimental Therapeutics 1993, 267:1076-1080.
10. Dhalla A.K., Wang W.Q., Dow J., Shryock J.C., Belardinelli L., Bhandari A. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. American Journal of Physiology - Heart and Circulatory Physiology 2009, 297:H1923-H1929.
11. Eichenbaum G., Pugsley M.K., Gallacher D.J., Towart R., McIntyre G., Shukla U., et al. Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2. British Journal of Pharmacology 2012, 10.1111/j.1476-5381.2012.01874.x.
12. Farkas A., Batey A.J., Coker S.J. How to measure electrocardiographic QT interval in the anaesthetized rabbit. Journal of Pharmacological and Toxicological Methods 2004, 50:175-185.
13. Fenichel R.R., Malik M., Antzelevitch C., Sanguinetti M., Roden D.M., Priori S.G., et al. Drug-induced torsades de pointes and implications for drug development. Journal of Cardiovascular Electrophysiology 2004, 15:475-495.
14. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001, 21:1468-1472.
15. Gallacher D.J., Van de W.A., van der L.H., Hermans A.N., Lu H.R., Towart R., et al. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome. Cardiovascular Research 2007, 76:247-256.
16. Guns P.J., Johnson D.M., Van Op den Bosch J., Weltens E., Lissens J. The electro-mechanical window in anaesthetized guinea-pigs: A new marker for Torsade de Pointes risk screening. British Journal of Pharmacology 2012, 166:689-701.
17. Hamlin R.L., Kijtawornrat A., Keene B.W., Hamlin D.M. QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles. Toxicological Sciences 2003, 76:437-442.
18. Hondeghem L.M. QT prolongation is an unreliable predictor of ventricular arrhythmia. Heart Rhythm 2008, 5:1210-1212.
19. Hondeghem L.M., Lu H.R., van Rossem K., De Clerck F. Detection of proarrhythmia in the female rabbit heart: Blinded validation. Journal of Cardiovascular Electrophysiology 2003, 14:287-294.
20. Johnson D.M., de Jong M.M., Crijns H.J., Carlsson L.G., Volders P.G. Reduced ventricular proarrhythmic potential of the novel combined ion-channel blocker AZD1305 versus dofetilide in dogs with remodeled hearts. Circulation. Arrhythmia and Electrophysiology 2012, 5:201-209.
21. 2+ release from the sarcoplasmic reticulum. Heart Rhythm 2011, 8:1823.
22. Johnson D.M., Heijman J., Pollard C.E., Valentin J.P., Crijns H.J., Abi-Gerges N., et al. I(Ks) restricts excessive beat-to-beat variability of repolarization during beta-adrenergic receptor stimulation. Journal of Molecular and Cellular Cardiology 2010, 48:122-130.
23. Kagstrom J., Laumola E.L., Poijes N., Johansson M., Ericson A.C. Assessment of the effects of changes in body temperature on cardiac electrophysiology in anaesthetised guinea pigs. Journal of Pharmacological and Toxicological Methods 2012, 65:1-7.
24. Lengyel C., Varro A., Tabori K., Papp J.G., Baczko I. Combined pharmacological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes. British Journal of Pharmacology 2007, 151:941-951.
25. Li X.W., Niu S.C., Zhang X.P., Lu J.Y., Bai F., Zhang L., et al. Differences of promethazine and terfenadine on ion channels in guinea pig ventricular myocytes. Chinese Medical Journal (English) 2006, 119:944-947.
26. Michael G., Kane K.A., Coker S.J. Adrenaline reveals the torsadogenic effect of combined blockade of potassium channels in anaesthetized guinea pigs. British Journal of Pharmacology 2008, 154:1414-1426.
27. Moss A.J., Robinson J.L., Gessman L., Gillespie R., Zareba W., Schwartz P.J., et al. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. The American Journal of Cardiology 1999, 84:876-879.
28. Oros A., Beekman J.D., Vos M.A. The canine model with chronic, complete atrio-ventricular block. Pharmacological & Therapeutics 2008, 119:168-178.
29. Oros A., Houtman M.J., Neco P., Gomez A.M., Rajamani S., Oosterhoff P., et al. Robust anti-arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action. British Journal of Pharmacology 2010, 161:162-175.
30. 2+-dependent arrhythmias: Implications for drug safety. Expert Opinion on Drug Safety 2009, 8:57-72.
31. Pugsley M.K., Authier S., Curtis M.J. Principles of safety pharmacology. British Journal of Pharmacology 2008, 154:1382-1399.
32. Pugsley M.K., Towart R., Authier S., Gallacher D.J., Curtis M.J. Non-clinical models: Validation, study design and statistical consideration in safety pharmacology. Journal of Pharmacological and Toxicological Methods 2010, 62:1-3.
33. Rosenbaum D.S., Jackson L.E., Smith J.M., Garan H., Ruskin J.N., Cohen R.J. Electrical alternans and vulnerability to ventricular arrhythmias. The New England Journal of Medicine 1994, 330:235-241.
34. Shimizu W., Ohe T., Kurita T., Kawade M., Arakaki Y., Aihara N., et al. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. Journal of the American College of Cardiology 1995, 26:1299-1309.
35. Testai L., Calderone V., Salvadori A., Breschi M.C., Nieri P., Martinotti E. QT prolongation in anaesthetized guinea-pigs: An experimental approach for preliminary screening of torsadogenicity of drugs and drug candidates. Journal of Applied Toxicology 2004, 24:217-222.
36. Thomsen M.B., Verduyn S.C., Stengl M., Beekman J.D., de Pater G., van Opstal J., et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 2004, 110:2453-2459.
37. Thomsen M.B., Volders P.G.A., Stengl M., Spätjens R.L.H.M., Beekman J.D.M., Bischoff U., et al. Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. Journal of Pharmacology and Experimental Therapeutics 2003, 307:776-784.
38. Towart R., Linders J.T., Hermans A.N., Rohrbacher J., van der Linde H.J., Ercken M., et al. Blockade of the I(Ks) potassium channel: An overlooked cardiovascular liability in drug safety screening?. Journal of Pharmacological and Toxicological Methods 2009, 60:1-10.
39. van der Linde H.J. Induction of β-adrenergic dependent TdP (LQT1-like) in fentanyl, α-chloralose and sodium pentobarbital anaesthetised beagle dogs. Journal of Pharmacological and Toxicological Methods 2009, 60:248.
40. van der Linde H.J., Van Deuren B., Somers Y., Loenders B., Towart R., Gallacher D.J. The electro-mechanical window: A risk marker for Torsade de Pointes in a canine model of drug induced arrhythmias. British Journal of Pharmacology 2010, 161:1444-1454.
41. Vargas H.M. A new preclinical biomarker for risk of Torsades de Pointes: Drug-induced reduction of the cardiac electromechanical window. British Journal of Pharmacology 2010, 161:1441-1443.
42. Volders P.G., Kulcsar A., Vos M.A., Sipido K.R., Wellens H.J., Lazzara R., et al. Similarities between early and delayed afterdepolarizations induced by isoproterenol in canine ventricular myocytes. Cardiovascular Research 1997, 34:348-359.
43. Wang W.Q., Robertson C., Dhalla A.K., Belardinelli L. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. Journal of Pharmacology and Experimental Therapeutics 2008, 325:875-881.
44. Wu L., Guo D., Li H., Hackett J., Yan G.X., Jiao Z., et al. Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. Heart Rhythm 2008, 5:1726-1734.
45. Yao X., Anderson D.L., Ross S.A., Lang D.G., Desai B.Z., Cooper D.C., et al. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. British Journal of Pharmacology 2008, 154:1446-1456.